Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Jan 14, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to give a medication called enoxaparin, also known as Lovenox, to help prevent blood clots in patients who have had surgery or trauma. Blood clots can be a serious problem for patients in critical care, and this study is comparing two doses: 30 mg given twice a day versus 40 mg given once a day. Researchers want to see which method is better at reducing the risk of blood clots and whether one method causes more bleeding complications than the other.

To be part of this trial, patients need to be at least 15 years old and admitted to the hospital for surgery or trauma care, where they would normally receive Lovenox to prevent blood clots. Patients will be randomly assigned to receive one of the two dosing regimens and will be closely monitored for signs of blood clots and bleeding. At the end of their hospital stay, an ultrasound will be performed to check for clots in their legs. This study is important because it may help improve treatments for preventing blood clots in critically ill patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admitted patients requiring prophylactic dosing of enoxaparin (Lovenox)
• • Admitted to the trauma or surgical service
• • Age greater than 15 years
• Exclusion Criteria:
• • Unable to obtain consent from patient or authorized representative
• • Presence of intracranial hemorrhage
• • Receiving therapeutic dose of enoxaparin (Lovenox)
• • Receiving other forms of anticoagulation
• • Presence of renal failure requiring non-standard dosing regimen